Integrilin Injection
Eptifibatide
0.75mg/ml
SCHERING-PLOUGH CORPORATION
| Pack size | 100ml Glass Vial |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | CITY MEDICAL STORE |
| Retail Price | 479.50 AED |
Available as:
Indications
Integrilin Injection is used for:
Myocardial infarction, Unstable angina, Angioplasty, Percutaneous coronary intervention (PCI)
Adult Dose
Intravenous
Unstable angina
Adult: 180 mcg/kg via IV inj followed by 2 mcg/kg per minute by IV infusion for up to 72 hr. If percutaneous coronary intervention (PCI) is performed during therapy, infusion should be continued for 18-24 hr after procedure, up to a maximum total duration of 96 hr of therapy.
Angioplasty
Adult: Initially, 180 mcg/kg via IV inj, to be given immediately before procedure, followed by 2 mcg/kg/minute via IV infusion. A second dose of 180 mcg/kg via IV inj should be given 10 minutes after the 1st dose. Continue infusion until hospital discharge or for up to 18-24 hr (minimum treatment duration: 12 hr).
Child Dose
Renal Dose
Renal Impairment
(CrCl <50 mL/min)
ACS: 180 mcg/kg IV, THEN continuous infusion 1 mcg/kg/min
PCI: 180 mcg/kg IV, THEN continuous infusion 1 mcg/kg/min with another 180 mcg/kg IV bolus 10 minutes after 1st one
Hemodialysis: Safety and using during hemodialysis not established
Administration
Contra Indications
Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation.
Precautions
Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm3; hemorrhagic retinopathy, drugs affecting haemostasis. Check APTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy.
Lactation: excretion in milk unknown; use with caution
Pregnancy-Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown; use with caution
Interactions
Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.
Adverse Effects
Side effects of Eptifibatide :
1-10%
Bleeding (8%), Hypotension (7%), Thrombocytopenia (2.3%), Injection site reaction
<1%
Hypersensitivity, Intracranial hemorrhage, Pulmonary hemorrhage, Thrombocytopenia, GI hemorrhage
Mechanism of Action
Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor thus preventing platelet aggregation and thrombosis.
Note
Integrilin 0.75mg/ml Injection manufactured by SCHERING-PLOUGH CORPORATION. Its generic name is Eptifibatide. Integrilin is availble in United Arab Emirates.
Farmaco UAE drug index information on Integrilin Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.